Furthermore, for renal cell cancer, sPD-L1 was found to be elevated in patients compared to healthy controls and in tyrosine kinase inhibitor-treated patients, high baseline sPD-L1 level was associated with poor OS [13,14]. Here, SPDL1 is linked to renal cell adenocarcinoma.